Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to evaluate short-duration therapy with the investigational hepatitis C protease inhibitor telaprevir (TVR, VX-950) in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) in treatment-naive, genotype 1-infected hepatitis C patients. The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, and suggested that 12 weeks of telaprevir-based therapy enabled some patients to clear the virus. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is developing telaprevir in collaboration with Tibotec.

"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."

PROVE 1 Summary

-- 88% and 79% of patients receiving telaprevir achieved a rapid viral response (RVR) as measured by plasma HCV RNA (less than)30 IU/mL and (less than)10 IU/mL, respectively, at 4 weeks.<
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:10/25/2014)...  The National Association of Drug Diversion Investigators ... Kentucky,s real-time, stop-sale pseudoephedrine ... Precursor Log Exchange (NPLEx) system automatically blocks unlawful ... helps flag meth offenders for law enforcement. Police ... "watch lists" that notify them via email when ...
(Date:10/25/2014)... , Oct. 24, 2014   Metanome, Inc. , ... metagenomic services and data analysis, was the genomic sequencing ... ) Phase I/II clinical trial of SER 109, an ... Clostridium difficile infections (CDI). Metanome ... Health,s R&D and clinical programs. Such genomic characterization has ...
(Date:10/25/2014)... October 24, 2014 ... has announced the addition of the  "Global ...  report to their offering.  ... Chinese Acne Medication Industry Report 2014 is ... current state of the global acne medication ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3
... , SAN DIEGO, Sept. 11 Calixa ... development and commercialization of novel antibiotics for the treatment ... in 20 posters at the Interscience Conference on Antimicrobial ... San Francisco on September 12 to 15, 2009. ...
... , , , ... preliminary schedule of events at the Cardiovascular Research Foundation,s (CRF) ... September 21st to Friday, September 25th, in San Francisco, CA. ... the world,s largest events for those performing cardiac diagnostics and ...
Cached Medicine Technology:Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundation's (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting 2
(Date:10/25/2014)... 26, 2014 Top 10 Best SEO ... the world. The site has recently compared many hosting ... HostMonster are among the most reliable Linux web hosting ... Top 10 Best SEO Hosting says, “The hosting suppliers ... companies who outperform their competitors on hosting features, uptime ...
(Date:10/25/2014)... The global HCIT outsourcing market is ... reach $50.4 billion by 2018 from $35 billion in ... pharmaceutical industry are driving the HCIT outsourcing market. These ... focus on core business, reduce operational and maintenance costs, ... reducing hiring and training costs), share risk, and quickly ...
(Date:10/25/2014)... The Wehrman Collaborative, LLC ... for disabled users by disabled users, has granted ... Mackin Educational Resources of Burnsville, Minnesota, for their ... to the Minnesota Alliance for Patient Safety of ... website. Both organizations have met WeCo’s ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Researchers who discovered antibiotics ... are cause for concern. The use of ... for human consumption contribute to the development of ... background information from the study. Each year ... 2 million people and kill about 23,000, according ...
Breaking Medicine News(10 mins):Health News:Top 10 Best SEO Hosting Announces That GreenGeeks.com And HostMonster Are Among The Most Reliable Linux Web Hosting Companies In 2014 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... infected with HIV in the UK rose last year to ... not know they are carrying the disease, a report said ... and nearly three-quarters of those were probably contracted in Africa., ... HIV sufferers had risen last year from an estimated 53,000 ...
... of anti-depressant medication and lifestyle change may be it is ... enjoy a splendid ride with a dolphin to help ease ... of biophilia that illustrates the dependence of human health on ... patients with mild to moderate depression were chosen for the ...
... Scientific Advisory Committee on Nutrition in the UK has said ... born with birth defects if folic acid were to be ... reducing commonly found neural tube defects like the spina bifida. ... be avoided if this simple precaution were to be taken. ...
... A new study reveals that antibiotics if taken limitlessly ... more than 10 times during childhood can increase the ... lymphatic system. , The study, conducted by Ellen ... Centre in Fremont, also found heavy use of non-steroidal ...
... its toll on Hong Kong teachers, with one in three ... ,Shouting at students in the class is affecting the ... said dry throats and husky and harsh voices were among ... developed voices like men., ,Researchers claim the problem ...
... Bacteria have been long regarded as something, only capable ... might soon change.// Thanks to the fervent efforts of ... UCSF who have created the first-ever bacterial photographs. ... at promoting the construction of simple biological machines is ...
Cached Medicine News:Health News:Swimming With Dolphins Can Help Ease Depression 2Health News:Bacterial Photographs Created By Student Scientists! 2
... watt halogen light source with ... ,SOLOS Endoscopy shares your commitment ... the highest quality care available ... development of advanced surgical instruments ...
Linvatecs single CCD camera heads offer high resolution with the convenience of programmable buttons for sterile field control of the printer and VCR. Available in "V and "C mount in NTSC and PAL....
... camera system offers the latest technology ... controller. Equipped with many of the ... expensive camera controllers, including edge enhancement, ... The controller is compatible and interchangeable ...
... Camera Systems provide the advanced functionality ... need for advanced training. Programmable, easy ... the flexibility needed to accommodate the ... Compatible with both autoclavable and non-autoclavable ...
Medicine Products: